Memorial Sloan Kettering experts are available to comment on the exciting new research presented at the 2015 American Association of Cancer Research annual meeting, including research in immunotherapy in pediatric cancers and melanoma, breast cancer, and many others. For more information and to set up interviews or access photos and video, email Rebecca Williams at firstname.lastname@example.org.
The largest hematology-oncology meeting in the world will take place in San Francisco from December 6 through 9. Memorial Sloan Kettering experts are available to comment on breaking news out of the meeting.
A collaborative team of leaders in the field of cancer immunology has made a key discovery that advances the understanding of why some patients respond to ipilimumab, an immunotherapy drug, while others do not.
The Centers for Medicare and Medicaid Services made a formal proposal to start covering low-dose CT scans for people who fall into a high-risk category for lung cancer. Epidemiologist Peter B. Bach, Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes and a thought leader on this topic, is available to discuss the importance of the proposal. For more information and to set up an interview, email our media staff at email@example.com.
MSK physicians Peter Bach and Leonard Saltz sparked a national debate in 2012 when they published an op-ed in the New York Times detailing Memorial Sloan Kettering’s refusal to include a new colorectal cancer drug on the hospital’s formulary because of its high cost. Drs. Bach and Saltz continue to engage the media in this discussion, appearing most recently on CBS's 60 Minutes. Both are available to discuss the burden these high prices have on patients, the current healthcare marketplace that allows cancer drugs to be priced so high, and what the medical community is poised to do about it. For more information and to set up an interview, email the Media Staff at firstname.lastname@example.org.
The first in a new class of immunotherapy drugs was granted FDA approval on September 4, 2014. MSK physicians played a major role in the clinical trials that led to its approval and are continuing to conduct trials using the therapy in melanoma and other cancers.
Physicians at Memorial Sloan Kettering have found that robotic surgery to remove a cancerous bladder did not reduce the risk of complications as compared with traditional open surgery. Findings were published this week in the New England Journal of Medicine. The study was conducted at MSK with surgeons experienced in both procedures and raises questions about the cost effectiveness of robotic surgery. For more information and to set up interviews with Dr. Bernard Bochner or Dr. Vincent Laudone, please contact Emily O’Donnell at email@example.com.
Memorial Sloan Kettering is proud and honored to announce it has been named the number one hospital for cancer care in the nation, according to U.S. News & World Report in its annual listing of Best Hospitals. Since the inception of the revered list 25 years ago, MSK has held either the first or second spot each year.